View source for 18552478. ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES simplified abstract (The Board of Trustees of the Leland Stanford Junior University)

=ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES=


==Organization Name==

[[:Category:The Board of Trustees of the Leland Stanford Junior University|The Board of Trustees of the Leland Stanford Junior University]]


[[Category:The Board of Trustees of the Leland Stanford Junior University]]

==Inventor(s)==

[[:Category:Robbie G. Majzner of Palo Alto CA (US)|Robbie G. Majzner of Palo Alto CA (US)]][[Category:Robbie G. Majzner of Palo Alto CA (US)]]

[[:Category:Aidan Tousley of Stanford CA (US)|Aidan Tousley of Stanford CA (US)]][[Category:Aidan Tousley of Stanford CA (US)]]

[[:Category:Maria Caterina Rotiroti of Stanford CA (US)|Maria Caterina Rotiroti of Stanford CA (US)]][[Category:Maria Caterina Rotiroti of Stanford CA (US)]]

==ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18552478 titled 'ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES

==Simplified Explanation==

The present disclosure is about an isolated recombinant cell that overexpresses a SLP-76 polypeptide, along with compositions and methods for producing these cells and corresponding SLP-76 molecules. It also includes methods for treating diseases like cancer with these compositions.

* Isolated recombinant cell overexpressing a SLP-76 polypeptide
* Compositions and methods for producing the isolated recombinant cells and SLP-76 molecules
* Methods for treating diseases, such as cancer, with these compositions

== Potential Applications ==
The technology can be used in the development of new treatments for diseases like cancer by targeting SLP-76.

== Problems Solved ==
This technology addresses the need for more effective treatments for diseases like cancer by utilizing isolated recombinant cells that overexpress SLP-76.

== Benefits ==
The benefits of this technology include potentially improved treatment options for diseases like cancer, as well as the ability to target specific cellular pathways for therapeutic purposes.

== Potential Commercial Applications ==
One potential commercial application of this technology could be the development of novel therapies for cancer treatment, which could have significant market potential.

== Possible Prior Art ==
Prior art may include research on SLP-76 and its role in cellular signaling pathways, as well as studies on recombinant cell technology for therapeutic applications.

=== Unanswered Questions ===

=== How does the overexpression of SLP-76 in isolated recombinant cells specifically impact cancer treatment? ===
The article does not delve into the specific mechanisms by which overexpressing SLP-76 in isolated recombinant cells can lead to improved cancer treatment outcomes.

=== Are there any potential side effects or limitations associated with using isolated recombinant cells overexpressing SLP-76 for disease treatment? ===
The potential drawbacks or limitations of this technology, such as off-target effects or immune responses, are not discussed in the article.


==Original Abstract Submitted==

The present disclosure generally relates to, inter alia, an isolated recombinant cell overexpressing a SLP-76 polypeptide. The disclosure also provides compositions and methods useful for producing the isolated recombinant cells and the corresponding SLP-76 molecules, as well as methods for treatment of diseases, such as cancer, with such compositions.



[[Category:A61K39/00]]
[[Category:A61P35/00]]
[[Category:C07K14/47]]
[[Category:C12N5/0783]]